Asset profile
Vicadrostat
Small molecule
Evidence outlook · registrational
Chronic Kidney Disease: registrational readout pending
Entered Phase 3 on reliable signal mid-stage evidence. Registrational readout expected around 2026-12-31.
NCT05182840: This was a randomized, quadruple-blind, placebo-controlled phase 2 trial in 586 patients with chronic kidney disease, comparing three doses of vicadrostat (3, 10, and 20 mg) against placebo, all on a background of empagliflozin or placebo. The primary endpoint was the change in urine albumin-to-creatinine ratio (UACR), a physiological measure that defines and stages CKD, at 14 weeks; the 10 mg and 20 mg doses achieved significantly larger reductions than placebo (p<0.0001) and the dose-response analysis was significant, so the primary endpoint was met. The 3 mg dose was only borderline (p=0.0499), making the overall result favorable but clearly dose-dependent.
Also in development:Hypertension · Phase 3Type 2 Diabetes · Phase 3Heart Failure · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
220 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 214 same-indication; 69 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Vicadrostat: this drug | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Lorundrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| QLS1410 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| SAL0140 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| VB19055 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| JX09 | Phase 1 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 |
…and 205 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2028 (2)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.